On October 31st local time, GlaxoSmithKline and Arrowhead Pharmaceuticals announced that they had reached an agreement with Janssen Pharmaceuticals, a subsidiary of Johnson&Johnson, to transfer the global exclusive further development and commercialization rights of JNJ-3989 to GlaxoSmithKline. JNJ-3989 was originally authorized by Yang Sen from Arrowhead in 2018. After the transaction is completed, GlaxoSmithKline will be responsible for making a total advance payment of approximately $1 billion and potential payments to Janssen Pharmaceuticals and Arrowhead. JNJ-3989 is an ongoing siRNA therapy drug for the treatment of chronic hepatitis B.